GSK PLC on Wednesday said that its vaccine candidate for the herpes simplex virus did not meet a primary efficacy objective in testing, and will not progress to the next phase of studies.
The London-based pharmaceuticals company made the decision based on data analysis from the phase two part of the TH HSV REC-003 trial.
This trial is a combined phase one/two proof-of-concept study to assess the potential clinical efficacy of GSK3943104, an early-stage therapeutic herpes simplex virus vaccine candidate.
According to results, GSK3943104 did not meet the study’s primary efficacy objective, and will not progress to phase three studies. No safety concern was observed.
GSK did however say that the study would continue for routine safety monitoring, and to generate follow-up data for ‘valuable insights’ into recurrent genital herpes.
‘Given the unmet medical need and burden associated with genital herpes, innovation in this area is still needed. GSK intends to evaluate the totality of all these data and other studies to progress future research and development of its HSV programme,’ the firm added.
Shares in GSK were trading 0.8% lower at 1,657.00 pence each in London on Wednesday morning.
Copyright 2024 Alliance News Ltd. All Rights Reserved.
